39629-86-2Relevant academic research and scientific papers
Synthesis and Biological Evaluation of Novel 5-Oxo-1-Phenylpyrrolidine-3-Carboxylic Acid Analogs
Devi, Poornima,Bishnoi, Abha,Srivastava, Krishna,Kumar, Sunil,Srivastava, Ankita,Fatma, Shaheen
, p. 271 - 276 (2019)
A number of 5-oxo-1-phenyl-4-(substituted methyl) pyrrolidine-3-carboxylic acid derivatives bearing pyrrolidine ring and methylamino residues in their structure were synthesized as potential antibacterial drugs. The chemical structures of all the compound
Analgesic and anticancer activity of benzoxazole clubbed 2-pyrrolidinones as novel inhibitors of monoacylglycerol lipase
Afzal, Obaid,Altamimi, Abdulmalik Saleh Alfawaz,Hassan, Md Quamrul,Riadi, Yassine,Shahroz, Mir Mohammad,Sharma, Hemant Kumar
, (2021/05/28)
Ten benzoxazole clubbed 2-pyrrolidinones (11–20) as human monoacylglycerol lipase inhibitors were designed on the criteria fulfilling the structural requirements and on the basis of previously reported inhibitors. The designed, synthesized, and characterized compounds (11–20) were screened against monoacylglycerol lipase (MAGL) in order to find potential inhibitors. Compounds 19 (4-NO2 derivative) and 20 (4-SO2 NH2 derivative), with an IC50 value of 8.4 and 7.6 nM, were found most active, respectively. Both of them showed micromolar potency (IC50 value above 50 μM) against a close analogue, fatty acid amide hydrolase (FAAH), therefore considered as selective inhibitors of MAGL. Molecular docking studies of compounds 19 and 20 revealed that carbonyl of 2-pyrrolidinone moiety sited at the oxyanion hole of catalytic site of the enzyme stabilized with three hydrogen bonds (~2 ?) with Ala51, Met123, and Ser122, the amino acid residues responsible for the catalytic function of the enzyme. Remarkably, the physiochemical and pharmacokinetic properties of compounds 19 and 20, computed by QikProp, were found to be in the qualifying range as per the proposed guideline for good orally bioactive CNS drugs. In formalin-induced nociception test, compound 20 reduced the pain response in acute and late stages in a dose-dependent manner. They significantly demonstrated the reduction in pain response, having better potency than the positive control gabapentin (GBP), at 30 mg/kg dose. Compounds 19 and 20 were submitted to NCI, USA, for anticancer activity screening. Compounds 19 (NSC: 778839) and 20 (NSC: 778842) were found to have good anticancer activity on SNB-75 cell line of CNS cancer, exhibiting 35.49 and 31.88% growth inhibition (% GI), respectively.
ANALGESIC DRUG USING PAC1 RECEPTOR ANTAGONISTIC DRUG
-
Paragraph 0110; 0120, (2021/06/26)
This invention relates to an analgesic drug comprising a compound represented by the following formula (I) or (II), wherein R1 is a C1-6-alkoxy group or a C1-6-haloalkoxy group; R2 is a hydrogen atom; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.
Pyrrolidin-2-one linked benzofused heterocycles as novel small molecule monoacylglycerol lipase inhibitors and antinociceptive agents
Altamimi, Abdulmalik Saleh Alfawaz,Bawa, Sandhya,Athar, Fareeda,Hassan, Md Quamrul,Riadi, Yassine,Afzal, Obaid
, p. 1418 - 1432 (2020/07/13)
Eighteen pyrrolidin-2-one linked benzothiazole, and benzimidazole derivatives (10–27) were designed and synthesized. The structure of the compounds was confirmed by elemental and spectral (IR, 1H-NMR and MS) data analysis. All the compounds wer
Synthesis of a novel and potent small-molecule antagonist of PAC1 receptor for the treatment of neuropathic pain
Takasaki, Ichiro,Ogashi, Haruna,Okada, Takuya,Shimodaira, Ayaka,Hayakawa, Daichi,Watanabe, Ai,Miyata, Atsuro,Kurihara, Takashi,Gouda, Hiroaki,Toyooka, Naoki
, (2019/12/09)
We recently identified novel small-molecule antagonists of the PACAP type I (PAC1) receptor using docking-based in silico screening followed by in vitro/vivo pharmacological assays. In the present study, we synthesized 18 novel derivatives based on the structure of PA-9, a recently developed antagonist of the PAC1 receptor, with a view to obtain a panel of compounds with more potent antagonistic and analgesic activities. Among them, compound 3d showed improved antagonistic activities. Intrathecal injection of 3d inhibited both pituitary adenylate cyclase-activating polypeptide (PACAP) and spinal nerve ligation-induced mechanical allodynia. The effects were more potent than PA-9. Compound 3d also showed anti-allodynic effects following oral administration. Hence, our results suggest that 3d may become an orally available analgesic in the treatment of the neuropathic pain.
1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS
-
Paragraph 0755-0756, (2020/11/30)
The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The novel compounds have formula (I): (Formula (I)) or are pharmaceutically acceptable salts thereof, wherein: R1a, R1b, R1c, R1d, R1e and R1f each independently represent hydrogen, optionally substituted C1-C6 alkyl or optionally substituted C3-C4 cycloalkyl, or R1b and R1c together form an optionally substituted C3-C6 cycloalkyl ring, or R1d and R1e together form an optionally substituted C3-C6 cycloalkyl ring; R2 represents hydrogen or optionally substituted C1-C6 alkyl; A represents an optionally further substituted 5 to 10 membered monocyclic or bicyclic heteroaryl, heterocyclyl or aryl ring; L represents a covalent bond or linker; B represents an optionally substituted 3 to 10 membered monocyclic or bicyclic heterocyclyl, heteroaryl, cycloalkyl or aryl ring; and when -A-L-B is at position x attachment to A is via a carbon ring atom of A, and either: A cannot be triazolopyridazinyl, triazolopyridinyl, imidazotriazinyl, imidazopyrazinyl or pyrrolopyrimidinyl; or B cannot be substituted with phenoxyl; or B cannot be cyclopentyl when L is an oxygen atom.
Site-Specific Synthesis of β-Fluorinated γ-Butyrolactams via Decarboxylative Fluorination of β-Carboxyl-γ-Butyrolactams
Phae-nok, Supasorn,Pohmakotr, Manat,Kuhakarn, Chutima,Reutrakul, Vichai,Soorukram, Darunee
, p. 4710 - 4720 (2019/08/01)
Monofluorinated cyclic nitrogen-containing compounds are synthetically useful scaffolds in organic synthesis and medicinal applications. In this report, AgNO3 mediated decarboxylative fluorination of β-carboxyl-γ-butyrolactams using Selectfluor as a fluorine source was described to achieve a site-specific synthesis of β-fluorinated γ-butyrolactams.
CD16A BINDING AGENTS AND USES THEREOF
-
Paragraph 00564, (2019/07/20)
Among other things, the present disclosure provides compounds, compositions thereof, and methods of using the same. In some embodiments, compounds of the present disclosure bind to Fc receptors, e.g., CD16a. In some embodiments, compounds of the present disclosure are useful for treating various conditions, disorders or diseases including cancer.
The discovery of new plant activators and scaffolds with potential induced systemic resistance: From jasmonic acid to pyrrolidone
Chang, Kang,Shi, Yanxia,Chen, Jianqin,He, Zenghui,Xu, Zheng,Zhao, Zhenjiang,Zhu, Weiping,Li, Honglin,Xu, Yufang,Li, Baoju,Qian, Xuhong
, p. 1849 - 1857 (2016/09/23)
Plants can develop multifaceted system resistance as a result of infection with pathogens, insects, and some specific microbes or after treatment with specific chemicals.1 Among them, systemic acquired resistance (SAR) and induced systemic resi
PRMT5 INHIBITORS AND USES THEREOF
-
Paragraph 00502, (2016/01/12)
Described herein are compounds of Formula (I)-(XIII), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
